Outlook Therapeutics Inc (OTLK) — Titan Protect Analysis

OTLK

Outlook Therapeutics Inc

Healthcare · ·

$0.78

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$98M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.06

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$6.00

+672% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 3 analysts covering this stock

About Outlook Therapeutics Inc

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therap

https://outlooktherapeutics.com

Country: United States Employees: 17 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.061

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0327

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.685

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-67.0%

Historical annualised return based on price data

Max Drawdown

-97.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.33

Very low correlation to market moves

52W High

$3.39

77% below the year high

52W Low

$0.16

383% above the year low

Avg Volume

14,191,255

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.13

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-11,006.8%

Profit from core operations before interest and tax

Free Cash Flow

$-25,471,416

Negative — the business is spending more than it generates

Revenue (TTM)

$333,141

Total revenue over the last 12 months

Net Income

$-60,956,488

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$6.00

Target Median

$6.00

Target Low

$0.50

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go